HSBC Holdings
VKTX icon

HSBC Holdings’s Viking Therapeutics VKTX Stock Holding History

HSBC Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,200
Closed -$360K – 3248
2025
Q4 		$360K Buy
+10,200
New +$361K ﹤0.01% 2448

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HSBC Holdings's VKTX Position: Q2 2026 in Review

HSBC Holdings reduced its Viking Therapeutics (VKTX) stake by 13% in Q2 2026, selling an estimated $76.5K and leaving 15,751 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

HSBC Holdings first reported a position in VKTX in Q1 2020 and has held it in 11 quarters since. The position peaked at $1.03M in Q3 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • HSBC Holdings held 15,751 shares of Viking Therapeutics worth $646K as of Q2 2026.
  • HSBC Holdings sold 2,368 Viking Therapeutics shares in Q2 2026, an estimated $76.5K.
  • Viking Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2161 holding.
  • HSBC Holdings first reported a position in Viking Therapeutics in Q1 2020 and has held it in 11 quarters since.
  • HSBC Holdings's Viking Therapeutics position peaked at $1.03M in Q3 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.